AstraZeneca: European regulators approve diabetes device

British pharmaceutical giant, AstraZeneca PLC (LON:AZN) today received approval from the European Commission for its Bydureon BCise ( a pre-filled pen device) which will enable patients with Type 2 Diabetes to medicate once a week.

Currently trading on a loss at 5,856.00 GBX −33.00 (0.56%) BST 08.37 as the UK Benchmark Index struggles to gain ground on the back of the strong GBP, this approval could have a major impact on Astrazeneca PLC’s profit margins.

An additional treatment option 

A statement from the company read: “Today’s approval of Bydureon BCise will enable us to offer an additional treatment option for patients with type-2 diabetes whose blood sugar levels are inadequately controlled by other glucose-lowering medicines together with diet and exercise.” as reported by Proactive Investors. 

AstraZeneca PLC frozen dividends could be offset by 2019

AstraZeneca PLC reported sales growth of almost 40% in its second quarter reports for 2018, and with this latest approval being just one of many pending patents (including 2 innovative cancer treatments), the company looks set to increase its revenues in 2019 for the first time in 4 years. Chief Executive, Pascal Soriot stated in July’s half-year report: “AstraZeneca’s rich pipeline and sharp commercial focus make us confident that we have in place the right conditions for our return to growth this year.” as reported in Bio Space.

Astrazenca PLC slowly emerging from sustained period of decline

AstraZeneca PLC (LON:AZN) seems to be remerging from a long period of decline with the share price rising by almost 20% this year and analysts predicting a 15% rise in earnings in 2019

As of 09:53 BST, Thursday, 30 August, AstraZeneca plc share price is 4,922.25p.

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.